Aclaris Therapeutics, Inc. (ACRS)
NASDAQ · Healthcare
Aclaris Therapeutics, Inc. Shareholder Equity 2017–2025
Aclaris Therapeutics, Inc. annual shareholder equity history from 2017 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Aclaris Therapeutics, Inc. shareholder equity as of December 31, 2025: 103.1M, a 33.73% decrease year-over-year.
- Aclaris Therapeutics, Inc. shareholder equity for 2025 were 103.1M, a 33.73% decrease from 2024.
- Aclaris Therapeutics, Inc. shareholder equity for 2024 were 155.6M, a 1.03% decrease from 2023.
- Aclaris Therapeutics, Inc. shareholder equity for 2023 were 157.2M, a 20.46% decrease from 2022.
- Aclaris Therapeutics, Inc. shareholder equity for 2022 were 197.6M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Aclaris Therapeutics, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $103 |
| 2024 | $156 |
| 2023 | $157 |
| 2022 | $198 |
| 2021 | $197 |
| 2020 | $38 |
| 2019 | $70 |
| 2018 | $215 |
| 2017 | $225 |
Aclaris Therapeutics, Inc. Shareholder Equity — FAQ
Aclaris Therapeutics, Inc. (ACRS) shareholder equity over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ACRS's shareholder equity history?
The chart and table above show Aclaris Therapeutics, Inc.'s shareholder equity by year and by quarter, including the growth rate.